Breaking News Instant updates and real-time market news.

ATRA

Atara Biotherapeutics

$13.60

-0.55 (-3.89%)

, CRSP

Crispr Therapeutics

$18.53

0.01 (0.05%)

04:55
12/07/17
12/07
04:55
12/07/17
04:55

Citigroup to hold a conference

2017 Global Healthcare Conference is being held in New York on December 6-7.

ATRA

Atara Biotherapeutics

$13.60

-0.55 (-3.89%)

CRSP

Crispr Therapeutics

$18.53

0.01 (0.05%)

INO

Inovio

$4.38

(0.00%)

RHHBY

Roche

$31.33

0.39 (1.26%)

OVID

Ovid Therapeutics

$11.41

0.33 (2.98%)

DBVT

DBV Technologies

$20.90

-0.12 (-0.57%)

NVS

Novartis

$83.18

-0.66 (-0.79%)

ZEAL

Zealand Pharma

$13.26

-0.31 (-2.28%)

GLPG

Galapagos NV

$85.47

0.03 (0.04%)

AMKR

Amkor Technology

$10.10

-0.15 (-1.46%)

BMY

Bristol-Myers

$60.97

-1.05 (-1.69%)

AGN

Allergan

$168.00

3.72 (2.26%)

MD

Mednax

$50.69

0.1 (0.20%)

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

  • 23

    Dec

  • 18

    Jan

  • 23

    Feb

  • 05

    Mar

  • 25

    Mar

  • 17

    May

ATRA Atara Biotherapeutics
$13.60

-0.55 (-3.89%)

10/05/17
JEFF
10/05/17
NO CHANGE
Target $30
JEFF
Buy
Atara's multiple sclerosis opportunity underappreciated, says Jefferies
Jefferies analyst Maury Raycroft views Atara Biotherapeutics' multiple sclerosis opportunity as "intriguing and under-the-radar." A multiple sclerosis update is expected from the company in a few weeks at the European Committee for Treatment and Research in Multiple Sclerosis meeting, Raycroft tells investors in a research note. He believes the catalyst "could be meaningful" for Atara. After receiving questions around the company's MS program ATA188, the analyst believes the opportunity may be "somewhat underappreciated." He keeps a Buy rating on Atara with a $30 price target.
12/14/16
SBSH
12/14/16
NO CHANGE
Target $8
SBSH
Sell
Citi says Atara Biotherapeutics sell thesis is working
Citi analyst Yigal Nochomovitz believes his thesis on Atara Biotherapeutics is working after the company this week said it will not be able to start Phase 3 trials by the end of 2016. The analyst keeps a Sell rating on the shares with an $8 price target.
12/06/17
JEFF
12/06/17
NO CHANGE
Target $30
JEFF
Buy
Atara shares compelling into year end, says Jefferies
Jefferies analyst Maury Raycroft believes near-term catalysts and long-term allogeneic potential position Atara Biotherapeutics as a compelling stock to own into year end. If the FDA agrees with the the comparability data for ATA129, and the decision may be imminent, the Phase III trials can start, Raycroft tells investors in a research note. He sees the start of the trials lifting the stock and keeps a Buy rating on Atara.
03/15/17
SBSH
03/15/17
NO CHANGE
Target $10
SBSH
Sell
Citi sees 50% downside risk in shares of Atara
Citi analyst Yigal Nochomovitz reiterates a Sell rating and $10 price target on shares of Atara Biotherapeutics following the stock's 40% rally this morning. The price target reflects 50% downside from current levels, the analyst points out. The stock rally came in the absence of new clinical data and with minimal updates on the pipeline, Nochomovitz tells investors in a research note. He continues to believe Atara's markets are relatively niche.
CRSP Crispr Therapeutics
$18.53

0.01 (0.05%)

03/28/17
CHDN
03/28/17
INITIATION
Target $23.5
CHDN
Buy
CRISPR Therapeutics initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated CRISPR Therapeutics with a Buy and a $23.50 price target saying upside from clinical leadership in CRISPR therapy offsets any potential downside from its IP exposure.
07/13/17
RHCO
07/13/17
INITIATION
Target $16
RHCO
Hold
CRISPR Therapeutics initiated with a Hold at SunTrust
SunTrust analyst Peter Larson initiated CRISPR Therapeutics with a Hold and a $16 price target.
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Crispr Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Crispr Therapeutics (CRSP) with a Perform rating saying the company is in a weaker patent position than competitor Editas Medicine (EDIT).
09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Crispr Therapeutics assumed with an Overweight at Barclays
Barclays assumed Crispr with an Overweight rating and a $29 price target, up from $22, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
INO Inovio
$4.38

(0.00%)

09/12/17
MAXM
09/12/17
NO CHANGE
MAXM
Inovio data positive, says Maxim
Maxim analyst Jason McCarthy says that the data on Inovio's (INO) INO-5150 for prostate cancer indicates that the drug "holds promise." He thinks that the company may find a new partner to replace Roche (RHHBY), and he keeps a $12 price target and a Buy rating on the shares.
10/06/17
SBSH
10/06/17
NO CHANGE
Target $10
SBSH
Buy
Zika data supportive of Inovio's platform, says Citi
The Phase 1 trial data for the company's Zika vaccine, published this week in the New England Journal of Medicine, are supportive for Inovio's platform beyond the immunogenicity data, Beatty tells investors in a research note. Inovio's platform may have the potential to generate functional antibodies in nearly 100% of people receiving a vaccine, which could also be useful in oncology if good antigen and tumor matches are made, Beatty adds. He believes the data support the view that Inovio is a leader in infectious disease vaccines. The analyst keeps a Buy rating on the shares with a $10 price target.
10/18/17
RBCM
10/18/17
INITIATION
RBCM
Outperform
Inovio initiated with an Outperform at RBC Capital
RBC Capital analyst Matthew Eckler initiated Inovio with an Outperform and $11 price target saying Phase III asset VGX-3100 has potential to be the first non-surgical approach for the treatment of HPV-driven cervical pre-cancers. Eckler also believes Inovio's early immuno-oncology platform also offer significant upside if any of the ongoing Phase1/Phase trials generate encouraging results.
10/18/17
10/18/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aaron's (AAN) initiated with a Neutral at Janney Capital. 2. Inovio (INO) initiated with an Outperform at RBC Capital. 3. Carrizo Oil & Gas (CRZO) reinstated with a Neutral at Goldman Sachs. 4. Goodrich Petroleum (GDP) assumed with a Buy at Seaport Global. 5. Krystal Biotech (KRYS) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RHHBY Roche
$31.33

0.39 (1.26%)

12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
11/20/17
BTIG
11/20/17
NO CHANGE
Target $242
BTIG
Buy
Shire selloff on Roche news seems overdone, says BTIG
BTIG analyst Timothy Chiang said today's weakness in Shire (SHPG) shares is overdone and creates a potential buying opportunity. While Roche's (RHBBY) emicizumab is likely to gain share at the expense of Shire's Advate, he does not expect a rapid conversion and thinks Shire's pipeline and platform seem overly discounted at current levels. Chiang has a Buy rating and $242 price target on Shire shares.
11/20/17
DBAB
11/20/17
NO CHANGE
Target $53
DBAB
Hold
Deutsche cuts Bioverativ target to $53 after positive Roche data
Deutsche Bank analyst Andrew Peters lowered his price target for Bioverativ (BIVV) to $53 from $65 and remains cautious on the shares following today's positive data from Roche's (RHHBY) Phase 3 study evaluating Hemlibra in noninhibitor hemophilia A patients. While full data is needed to better understand the clinical and competitive profile, the data reported today suggest Hemlibra will likely pressure the longevity and sustainability of Bioverativ's Eloctate franchise, Peters told investors earlier in a research note. The analyst reiterated a Hold rating on Bioverativ shares. The stock closed the trading day down 9.5% to $50.76. Shire (SHPG), another company with a hemophilia franchise, closed today down 4% to $141.37 while Roche rallied 6% to $30.82.
11/22/17
COWN
11/22/17
NO CHANGE
Target $105
COWN
Outperform
Impressive Venclexta abstract positive for AbbVie, says Cowen
Cowen analyst Steven Scala said a late breaking ASH abstract showed impressive data for AbbVie's Venclexta drug used in chronic lymphocytic leukemia. The analyst has modeled $2.6N in sales in 2024 and company guidance suggests sales could reach $6B in 2025. Scala reiterated his Outperform rating and $105 price target on AbbVie shares.
OVID Ovid Therapeutics
$11.41

0.33 (2.98%)

05/30/17
SBSH
05/30/17
INITIATION
Target $21
SBSH
Buy
Ovid Therapeutics initiated with a Buy at Citi
Target $21.
05/30/17
05/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ovid Therapeutics (OVID) was initiated with a Buy at Citi and an Outperform at William Blair, JMP Securities, and Cowen. 2. Antero Midstream Partners (AM) was resumed with an Overweight at Morgan Stanley, initiated with an Outperform at Credit Suisse, and reinstated with an Overweight at Barclays. 3. Antero Midstream GP (AMGP) was initiated with an Overweight at Morgan Stanley, JPMorgan, and Barclays, an Outperform at Baird and Credit Suisse, a Market Perform at Wells Fargo, a Strong Buy at Raymond James, a Buy at Goldman Sachs, Ladenburg, and DA Davidson, as well as a Hold at Stifel. 4. Biohaven Pharmaceutical (BHVN) was initiated with an Outperform at William Blair, an Overweight at Piper Jaffray and Barclays, as well as a Buy at Needham. 5. Pieris Pharmaceuticals (PIRS) initiated with a Buy at Rodman & Renshaw. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/30/17
JMPS
05/30/17
INITIATION
JMPS
Outperform
Ovid Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Jason Butler started coverage of Ovid with a $26 price target and an Outperform rating. The analyst says that the company has "expertise" and a good track record. He notes that the company has developed a treatment, currently undergoing a Phase 2 trial ,for Angelman Syndrome, for which there are no approved treatments and no other drug in development. Butler adds that Ovid is developing a treatment for rare epileptic encephalopathies in conjunction with Takeda.
05/30/17
WBLR
05/30/17
INITIATION
WBLR
Outperform
Ovid Therapeutics initiated with an Outperform at William Blair
William Blair analyst Tim Lugo started Ovid Therapeutics with an Outperform rating saying the company is an "emerging player" in rare neurologic disorders.
DBVT DBV Technologies
$20.90

-0.12 (-0.57%)

11/30/17
JEFF
11/30/17
NO CHANGE
Target $101
JEFF
Buy
AnaptysBio shares could rally $30 on Q1 data, says Jefferies
Jefferies analyst Biren Amin is out with his expectations for ANB020 ahead of AnaptysBio's (ANAB) Phase II data in adult severe peanut allergy expected in Q1 of 2018. The analyst thinks ANB020 could confer peanut tolerance of at least one peanut at the one month time point in about 35%-50% of ANB020 patients. Such an effect is "clearly much earlier than seen with peanut immunotherapy," Amin tells investors in a research note. The analyst thinks immune desensitization therapies, like the ones being developed by DBV Technologies (DBVT) and Aimmune (AIMT), leave "lots of room for improvement. Depending on the strength of data, AnaptysBio shares could move $20-$30 on the Q1 readout, Amin contends. He keeps a Buy rating on the shares with a $101 price target.
11/21/17
DBAB
11/21/17
NO CHANGE
Target $30
DBAB
Buy
DBV study checks safety box for approval, says Deutsche Bank
Deutsche Bank analyst Andrew Peters says yesterday's data from DBV Technologies suggests Viaskin Peanut is well tolerated with no unexpected adverse events. The study also fulfills the regulatory safety database requirements for the program, which adds comfort around the regulatory submission process, Peters tells investors in a research note. The analyst remains bullish on the overall dataset despite the failed Pepites study, and he keeps a Buy rating on DBV with a $30 price target.
11/20/17
JEFF
11/20/17
NO CHANGE
Target $37
JEFF
Buy
Jefferies still sees better than 50% odds for DBV approval
Jefferies analyst Eun Yang says DBV Technologies' Phase 3 safety data this morning demonstrate "similar, favorable safety" versus the prior Phase 3 trial. The analyst expects DBV to file a Biologics License Application in the first half of 2018 and continues to see greater than 50/50 likelihood for FDA approval. Yang has a Buy rating on the shares with a $37 price target.
11/20/17
SBSH
11/20/17
NO CHANGE
Target $57
SBSH
Buy
DBV safety study data contained few surprises, says Citi
Citi analyst Liav Abraham says this morning's headline data from DBV Technologies' Phase III Viaskin Peanut safety study yielded few surprises, with the study results "largely confirmatory of the benign safety profile" seen thus far in other clinical trials. The regulatory path forward for Viaskin Peanut with FDA remains unclear, the analyst adds. She believes DBV is likely to receive guidance from the FDA to file a Biologics License Application for Viaskin Peanut based on the totality of the data from the clinical trials thus far, and for a panel to address the approvability of the therapy. Abraham has a Buy rating on the shares with a $57 price target.
NVS Novartis
$83.18

-0.66 (-0.79%)

12/01/17
SBSH
12/01/17
DOWNGRADE
Target $380
SBSH
Neutral
Regeneron downgraded to Neutral from Buy at Citi
Citi analyst Robyn Karnauskas downgraded Regeneron Pharmaceuticals (REGN) to Neutral and cut her price target for the shares to $380 from $480. The biotechnology company closed yesterday up 1% to $361.86. The analyst believes the competitive threat from Novartis' (NVS) vision-loss drug RTH258 is being underappreciated by the market. It is hard to believe that RTH258 would not have a price impact, at minimum, on Regeneron's Eylea, Karnauskas tells investors in a research note. The analyst points out that her dermatologist survey came back bullish for Regeneron's Dupixent. While she expects the drug to beat expectations for 2018, the analyst feels this won't be enough to offset the overhang on shares from Eylea competition.
12/01/17
WELS
12/01/17
NO CHANGE
WELS
Wells not seeing Amazon talks as good news for Mylan, others
CNBC last night reported that Amazon.com (AMZN) is in exploratory talks with Mylan (MYL) and Novartis' Sandoz (NVS) regarding a potential entry into the pharmacy space. While the market might consider this good news for Mylan and other generics as a sign of potential preferred supplier agreements, Wells Fargo analyst David Maris says he's more cautious. Amazon entering the pharmacy market could be a negative headwind for retail generics and potentially branded over-the-counter products, Maris argues. He believes Amazon would source at competitive prices and that "increased price transparency may cause traditional retailers to push harder for price concessions."
12/01/17
WELS
12/01/17
NO CHANGE
Target $1525
WELS
Outperform
Amazon price target raised to $1,525 from $1,430 at Wells Fargo
Wells Fargo analyst Ken Sena raised his price target for Amazon.com (AMZN) to $1,525 to reflect increased outer-year estimates for Web Services as well as a higher sum-of-the-parts valuation. The stock closed yesterday up $15.48 to $1,176.75. The analyst highlights the "very successful" five-day Amazon Wed Services conference in Las Vegas, "record-breaking" early holiday sales data, and another healthcare industry development with CNBC reporting the company is in talks with generic manufacturers Mylan (MYL) and Novartis (NVS). Sena sees an increasing likelihood that Amazon "ultimately becomes a disruptor" in healthcare, with generics representing a potential point of entry. The Wells Fargo Healthcare team sees generics as a "simple entry point" in pharma as it involves many players with ready supply and a price competitive market, Sena tells investors in a research note. The analyst keeps an Outperform rating on Amazon.
12/06/17
BOFA
12/06/17
DOWNGRADE
BOFA
Underperform
Novartis downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Graham Perry downgraded Novartis to Underperform citing recent share strength, Cosentyx competition, and lack of catalysts.
ZEAL Zealand Pharma
$13.26

-0.31 (-2.28%)

09/05/17
09/05/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Owens-Illinois (OI) initiated with a Neutral at UBS. 2. Akamai (AKAM) initiated with a Neutral at Credit Suisse. 3. Zealand Pharma (ZEAL) was initiated with a Buy at Needham and Guggenheim while being initiated with an Overweight at Morgan Stanley. 4. YogaWorks (YOGA) was initiated with an Outperform at Cowen, an Overweight at Stephens, and a Buy at Roth Capital and Guggenheim. 5. Red Hat (RHT) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/17
09/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX), JD.com (JD) initiated with an Outperform at Wells Fargo, and Baidu (BIDU) were initiated with an Outperform at Wells Fargo. 2. Zealand Pharma (ZEAL) initiated with a Buy at Goldman Sachs. 3. Olin (OLN) initiated with a Buy at Citi. 4. First Horizon (FHN) resumed with an Equal Weight at Morgan Stanley. 5. CRH (CRH) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/17
GSCO
09/27/17
INITIATION
Target $25
GSCO
Buy
Zealand Pharma initiated with a Buy at Goldman Sachs
Goldman analyst Keyur Parekh initiated Zealand Pharma with a Buy and $26 price target. The analyst believes Zealand's pipeline, with two key assets being glepaglutide for short bowel syndrome and dasiglucagon with multiple potential indications, is underappreciated and will drive share upside.
09/05/17
NEED
09/05/17
INITIATION
NEED
Buy
Zealand Pharma initiated with a Buy at Needham
Needham analyst Alan Carr started coverage of Zealand with a $26 price target and a Buy rating. After analyzing Phase 2 data for the company's lead drugs glepaglutide and dasiglucagon for the treatment of Short Bowel Syndrome and Acute Severe Hypoglycemia, respectively, Carr thinks that the drugs' Phase 3 data will be "favorable." He estimates that dasiglucagon will generate peak revenue of $360M and predicts that glepaglutide will generate peak revenue of $500M.
GLPG Galapagos NV
$85.47

0.03 (0.04%)

08/14/17
JEFF
08/14/17
NO CHANGE
JEFF
Buy
Expert IPF call positive for FibroGen, says Jefferies
Jefferies analyst Michael Yee says his call with two idiopathic pulmonary fibrosis experts was net positive for FibroGen (FGEN). Based on the available data, the experts estimated a 30%-40%-plus probability of success in Phase 3 for the company. The experts were "more conservative in the interpretation" of the data reported by Galapagos NV (GLPG), Yee tells investors in a research note. He reiterates a Buy rating on FibroGen given the "underappreciated value" for FG-3019 in IPF.
08/11/17
STFL
08/11/17
UPGRADE
Target $101
STFL
Buy
Stifel upgrades Galapagos with $101 target on 'clearly positive' data
Stifel analyst Adam Walsh upgraded Galapagos NV to Buy from Hold and raised his price target for the shares to $101 from $83. The stock closed yesterday up 11%, or $7.89, to $81.06. The early Phase 2 results for wholly-owned GLPG1690 in idiopathic pulmonary fibrosis were "clearly positive," Walsh tells investors in a research note. The analyst included the drug in his model with a "very reasonable" 10% probability of success. Further, he sees "reduced downside risk" associated with Galapagos' cystic fibrosis triple combo.
09/15/17
STFL
09/15/17
NO CHANGE
Target $120
STFL
Buy
Galapagos NV price target raised to $120 from $101 at Stifel
After hosting a call with two key opinion leaders on idiopathic pulmonary fibrosis, Stifel analyst Adam Walsh noted that the physicians expressed the view that the efficacy of GLPG1690 in the Phase 2 FLORA trial "was as good as one could have hoped for." As a result of the positive physician feedback, he increased his probability of success for '1690 to 15% from 10% and raised his price target on Galapagos to $120 from $101. Walsh keeps a Buy rating on Galapagos shares.
09/14/17
RBCM
09/14/17
INITIATION
Target $98
RBCM
Sector Perform
Galapagos NV initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started Galapagos NV with a Sector Perform rating and $98 price target.
AMKR Amkor Technology
$10.10

-0.15 (-1.46%)

BMY Bristol-Myers
$60.97

-1.05 (-1.69%)

11/08/17
LEER
11/08/17
NO CHANGE
LEER
Outperform
Leerink sees Five Prime recovering some of yesterday's losses
After hosting an investor call to obtain additional information on the efficacy and safety profile of cabiralizumab in pancreatic cancer, Leerink analyst Michael Schmidt expects shares Five Prime Therapeutics (FPRX) will recover some of the losses from yesterday. The efficacy observed in yesterday's data look "quite promising," while safety looks very similar to what has been seen in Opdivo monotherapy trials historically, Schmidt tells investors in a research note. He notes that Five Prime partner Bristol-Myers (BMY) remains highly engaged in the cabiralizumab program. The analyst maintains an Outperform rating on Five Prime shares. The stock in midday trading is up 15%, or $3.85, to $29.71.
11/30/17
GABE
11/30/17
NO CHANGE
Target $133
GABE
Buy
Incyte a top biotech pick for 2018 at Gabelli
Gabelli analyst Jing He highlighted Incyte as his top biotech pick for 2018 telling investors shares are undervalued and should benefit from the Epa melanoma data readout in first half 2018. The analyst said shares are trading near a 52-week low despite progress in the pipeline and believes competitors Bristol-Myers (BMY) and NewLink's (NLNK) IDO inhibitors are a few years behind Epa in development. Further, as tax reform gains more clarity, He believes M&A oncology deals could pickup and views Incyte as an attractive takeover target. Jing He rates Incyte a Buy with a $133 price target.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
AGN Allergan
$168.00

3.72 (2.26%)

12/05/17
WELS
12/05/17
NO CHANGE
WELS
Outperform
Allergan selloff on Revance data overdone, says Wells Fargo
Wells Fargo analyst David Maris views the selloff today in shares of Allergan (AGN) following Revance Therapeutics' (RVNC) frown lines data as overdone. While the positive Phase III results are good news for Revance, the data are yet to be seen in detail and it is unclear how significant a competitor RT002 could be to Allergan's Botox, Maris tells investors in a post-close research note. The analyst says that while RT002 showed statistically significant results at week 24 versus placebo in a key secondary endpoint, the measurement of this endpoint does not seem to match the FDA's published draft guidance. As such, it is unclear if the data will be enough to get a six-month duration claim on the RT002 label, Maris argues. The analyst keeps an Outperform rating on Allergan shares, which closed the trading day down $2.62 to $164.28.
12/05/17
PIPR
12/05/17
NO CHANGE
Target $51
PIPR
Overweight
Piper ups Revance price target to $51 on 'impressive' data
Piper Jaffray analyst David Amsellem raised his price target for Revance Therapeutics (RVNC) to $51 from $28 saying this morning's Phase III results for RT002 are "impressive." The stock in afternoon trading is up 38%, or $10.00, to $36.00. The company can now credibly claim that its "frown lines" treatment confers "significant benefit" for a sizable group of patients out to six months, Amsellem tells investors in an intraday research note. He thinks RT002 could offer the potential not only for less frequent procedures compared to Allergan's (AGN) Botox but also the potential for better treatment outcomes. Allergan in afternoon trading is down $2.13 to $164.72. The analyst believes the question now for RT002 is not approvability, but rather what a differentiated label would look like. Amsellem also feels the data "should embolden" Revance to "cast a wider net in terms of the pursuit of additional indications." He reiterates an Overweight rating on the shares.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $240
SBSH
Buy
RT002 likely to have limited impact on Allergan's Botox, says Citi
Citi analyst Liav Abraham does not view today's headline data from Revance Therapeutics (RVNC) long-acting botulinum toxin RT002 as a meaningful commercial threat to Allergan's (AGN) Botox franchise. The analyst, however, acknowledges that the data may continue to raise concerns around the durability of Allergan's Botox aesthetic revenue. Revance is likely to struggle to compete with Allergan's commercial presence in the market, Abraham tells investors in an intraday research note. She notes that Botox maintains the "lion's share of the aesthetic botulinum toxin market" despite the presence of competitors Xeomin and Dysport. The analyst sees RT002 having a limited impact on Botox and she keeps a Buy rating on Allergan with a $240 price target.
12/06/17
MSCO
12/06/17
NO CHANGE
MSCO
Overweight
Morgan Stanley maintains Botox sales projections after Revance drug data
While Morgan Stanley analyst David Risinger said Revance (RVNC) presented "compelling" Phase 3 investigator-assessed responder rates for RT002 compared to Allergan's (AGN) Botox, he contends that patient-assessed rates, which look much closer in comparison, may be more reflective of potential uptake. Risinger, who believes aesthetics market retreatment decisions will mainly be determined by patients, maintains his Botox sales projections and Overweight rating on Allergan after yesterday's report of data from its competitor.
MD Mednax
$50.69

0.1 (0.20%)

09/18/17
09/18/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Caterpillar (CAT) upgraded to Buy from Neutral at UBS with analyst Steven Fisher saying his firm's latest analysis of private non-residential construction ex-Power shows a re-acceleration in activity in the fourth quarter and mid-single digit growth into 2018. 2. Mednax (MD) upgraded to Overweight from Sector Weight at KeyBanc analyst Jason Gurda saying he sees the company's operating headwinds moderating over the next few quarters and growth in its third specialty, radiology, accelerating in the the near-term. 3. Infosys (INFY) upgraded to Neutral from Sell at Goldman Sachs with the firm saying management uncertainty and guidance risk is already priced in. 4. Klondex Mines (KLDX) upgraded to Buy from Hold at Canaccord. 5. BP (BP) upgraded to Outperform from Market Perform at BMO Capital with analyst Brendan Warn saying he thinks the company's free cash flow will be boosted by "delivery of new upstream volumes, premium downstream product demand and improving (refining marker margin)." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/17
KEYB
09/18/17
UPGRADE
Target $51
KEYB
Overweight
Mednax upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Jason Gurda upgraded Mednax to Overweight with a $51 price target. The analyst sees the company's operating headwinds moderating over the next few quarters and growth in its third specialty, radiology, accelerating in the the near-term. He thinks the shares at current levels are "relatively inexpensive."
09/17/17
KEYB
09/17/17
UPGRADE
Target $51
KEYB
Overweight
MEDNAX upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Jason Gurda upgraded MEDNAX to Overweight with a $51 price target. Gurda expects a moderation in operating headwinds over the next few quarters, cost cutting/new revenue to offset some of the headwinds, thinks the radiology business is poised for strong growth, and views the company as a potential acquisition target over the next few years.
10/16/17
BMOC
10/16/17
INITIATION
Target $46
BMOC
Market Perform
Mednax initiated with a Market Perform at BMO Capital
BMO Capital analyst Matt Borsch initiated Mednax with an Market Perform and $46 price target due to unfavorable macroeconomic factors coupled with a slower-paced acquisition pipeline could lead to additional near-term volatility in financial results.

TODAY'S FREE FLY STORIES

ACN

Accenture

$161.71

-0.725 (-0.45%)

13:32
11/13/18
11/13
13:32
11/13/18
13:32
Hot Stocks
Accenture adding 300 jobs in Seattle innovation hub by the end of 2020 »

Accenture opened a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

ACHC

Acadia

$36.69

-5.25 (-12.52%)

13:32
11/13/18
11/13
13:32
11/13/18
13:32
Hot Stocks
Breaking Hot Stocks news story on Acadia »

Acadia off lows, remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$9.60

0.11 (1.16%)

13:30
11/13/18
11/13
13:30
11/13/18
13:30
Hot Stocks
Ford reports October China sales down 45% to 58,204 vehicles »

Ford Motor Company China…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 13

    Dec

USAT

USA Technologies

$4.93

-0.29 (-5.56%)

13:30
11/13/18
11/13
13:30
11/13/18
13:30
Options
Bullish option play in USA Technologies as shares fall to 52-week lows »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SWK

Stanley Black & Decker

$126.06

4.27 (3.51%)

13:25
11/13/18
11/13
13:25
11/13/18
13:25
Options
Black and Decker call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KOP

Koppers Holdings

$21.37

1.17 (5.79%)

13:24
11/13/18
11/13
13:24
11/13/18
13:24
Hot Stocks
Koppers Holdings exec Johnson acquires 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 26

    Nov

  • 27

    Nov

ACHC

Acadia

$40.50

-1.44 (-3.43%)

13:23
11/13/18
11/13
13:23
11/13/18
13:23
Hot Stocks
Breaking Hot Stocks news story on Acadia »

Acadia Healthcare drops…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACHC

Acadia

$40.88

-1.06 (-2.53%)

13:22
11/13/18
11/13
13:22
11/13/18
13:22
Hot Stocks
Breaking Hot Stocks news story on Acadia 

Acadia trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROW

T. Rowe Price

$96.11

0.52 (0.54%)

, PZZA

Papa John's

$55.64

-0.23 (-0.41%)

13:21
11/13/18
11/13
13:21
11/13/18
13:21
Hot Stocks
Breaking Hot Stocks news story on T. Rowe Price, Papa John's »

T. Rowe Price reports…

TROW

T. Rowe Price

$96.11

0.52 (0.54%)

PZZA

Papa John's

$55.64

-0.23 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

13:20
11/13/18
11/13
13:20
11/13/18
13:20
Hot Stocks
Breaking Hot Stocks news story  »

USA Technologies trading…

ACHC

Acadia

$41.44

-0.5 (-1.19%)

13:17
11/13/18
11/13
13:17
11/13/18
13:17
Hot Stocks
Breaking Hot Stocks news story on Acadia »

Acadia trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOYA

Voya Financial

$45.98

1.395 (3.13%)

13:17
11/13/18
11/13
13:17
11/13/18
13:17
Hot Stocks
Breaking Hot Stocks news story on Voya Financial »

Voya Financial shares up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
11/13/18
11/13
13:17
11/13/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOYA

Voya Financial

$46.07

1.485 (3.33%)

13:16
11/13/18
11/13
13:16
11/13/18
13:16
Hot Stocks
Voya Financial capital deployment plans will emphasize share buybacks »

Voya Financial CEO Rodney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
11/13/18
11/13
13:16
11/13/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
11/13/18
11/13
13:15
11/13/18
13:15
Hot Stocks
Breaking Hot Stocks news story  »

USA Technologies trading…

VOYA

Voya Financial

$46.04

1.455 (3.26%)

13:15
11/13/18
11/13
13:15
11/13/18
13:15
Hot Stocks
Voya Financial lays out plans for at least 10% annual earnings growth »

Voya Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TROW

T. Rowe Price

$95.98

0.39 (0.41%)

, UPWK

Upwork

$18.19

0.59 (3.35%)

13:13
11/13/18
11/13
13:13
11/13/18
13:13
Hot Stocks
Breaking Hot Stocks news story on T. Rowe Price, Upwork »

T. Rowe Price reports…

TROW

T. Rowe Price

$95.98

0.39 (0.41%)

UPWK

Upwork

$18.19

0.59 (3.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

VOYA

Voya Financial

$46.21

1.625 (3.64%)

13:11
11/13/18
11/13
13:11
11/13/18
13:11
Hot Stocks
Breaking Hot Stocks news story on Voya Financial »

Voya sees dividend…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

VOYA

Voya Financial

$46.38

1.795 (4.03%)

13:10
11/13/18
11/13
13:10
11/13/18
13:10
Hot Stocks
Breaking Hot Stocks news story on Voya Financial »

Voya Financial targets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

VOYA

Voya Financial

$46.38

1.795 (4.03%)

13:10
11/13/18
11/13
13:10
11/13/18
13:10
Earnings
Breaking Earnings news story on Voya Financial »

Voya Financial sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

13:08
11/13/18
11/13
13:08
11/13/18
13:08
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

CVE

Cenovus Energy

$8.51

-0.185 (-2.13%)

13:05
11/13/18
11/13
13:05
11/13/18
13:05
Options
Cenovus Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFY

Infosys

$9.39

0.06 (0.64%)

12:58
11/13/18
11/13
12:58
11/13/18
12:58
Hot Stocks
Infosys to open technology and innovation hub in Texas, hire 500 workers by 2020 »

Infosys announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

SNE

Sony

$51.64

0.09 (0.17%)

, MSFT

Microsoft

$107.45

0.56 (0.52%)

12:56
11/13/18
11/13
12:56
11/13/18
12:56
OnTheFly
Game On: Take-Two says 'Red Dead 2' has outsold first 'RDR' in just eight days »

Welcome to "Game On," The…

SNE

Sony

$51.64

0.09 (0.17%)

MSFT

Microsoft

$107.45

0.56 (0.52%)

T

AT&T

$30.63

-0.17 (-0.55%)

NTDOY

Nintendo

$0.00

(0.00%)

ATVI

Activision Blizzard

$52.93

-0.97 (-1.80%)

TTWO

Take-Two

$108.52

-0.51 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 28

    Nov

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.